Literature DB >> 17922029

Complex patterns of ETS gene alteration arise during cancer development in the human prostate.

J Clark1, G Attard, S Jhavar, P Flohr, A Reid, J De-Bono, R Eeles, P Scardino, J Cuzick, G Fisher, M D Parker, C S Foster, D Berney, G Kovacs, C S Cooper.   

Abstract

An ERG gene 'break-apart' fluorescence in situ hybridization (FISH) assay has been used to screen whole-mount prostatectomy specimens for rearrangements at the ERG locus. In cancers containing ERG alterations the observed pattern of changes was often complex. Different categories of ERG gene alteration were found either together in a single cancerous region or within separate foci of cancer in the same prostate slice. In some cases the juxtaposition of particular patterns of ERG alterations suggested possible mechanisms of tumour progression. Prostates harbouring ERG alterations commonly also contained cancer that lacked rearrangements of the ERG gene. A single trans-urethral resection of the prostate specimen examined harboured both ERG and ETV1 gene rearrangements demonstrating that the observed complexity may, at least in part, be explained by multiple ETS gene alterations arising independently in a single prostate. In a search for possible precursor lesions clonal ERG rearrangements were found both in high grade prostatic intraepithelial neoplasia (PIN) and in atypical in situ epithelial lesions consistent with the diagnosis of low grade PIN. Our observations support the view that ERG gene alterations represent an initiating event that promotes clonal expansion initially to form regions of epithelial atypia. The complex patterns of ERG alteration found in prostatectomy specimens have important implications for the design of experiments investigating the clinical significance and mechanism of development of individual prostate cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922029     DOI: 10.1038/sj.onc.1210843

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

2.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

3.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

4.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Authors:  Veit J Scheble; Martin Braun; Rameen Beroukhim; Craig H Mermel; Christian Ruiz; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; Markus Reischl; Rainer Kuefer; David Schilling; Falko Fend; Glen Kristiansen; Matthew Meyerson; Mark A Rubin; Lukas Bubendorf; Sven Perner
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

5.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 6.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Authors:  Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

Review 8.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

9.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

10.  C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?

Authors:  L Boldrini; R Bartoletti; M Giordano; F Manassero; C Selli; M Panichi; L Galli; F Farci; P Faviana
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.